Roundview Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.67M Buy
30,467
+618
+2% +$133K 0.42% 61
2026
Q1
$6.49M Buy
29,849
+362
+1% +$80.3K 0.4% 60
2025
Q4
$6.74M Buy
29,487
+86
+0.3% +$19.6K 0.41% 57
2025
Q3
$6.81M Buy
29,401
+151
+0.5% +$30.7K 0.43% 53
2025
Q2
$5.43M Buy
29,250
+329
+1% +$61.1K 0.36% 63
2025
Q1
$6.06M Buy
28,921
+201
+0.7% +$39.1K 0.44% 54
2024
Q4
$5.1M Buy
28,720
+765
+3% +$141K 0.36% 65
2024
Q3
$5.52M Buy
27,955
+87
+0.3% +$16.2K 0.4% 60
2024
Q2
$4.78M Buy
27,868
+428
+2% +$70.9K 0.38% 60
2024
Q1
$5M Buy
27,440
+722
+3% +$124K 0.41% 58
2023
Q4
$4.14M Sell
26,718
-5,554
-17% -$810K 0.38% 59
2023
Q3
$4.81M Sell
32,272
-56
-0.2% -$8.22K 0.48% 50
2023
Q2
$4.36M Buy
32,328
+99
+0.3% +$14.5K 0.43% 57
2023
Q1
$5.14M Buy
32,229
+331
+1% +$50.6K 0.54% 49
2022
Q4
$5.16M Buy
31,898
+442
+1% +$67.8K 0.59% 46
2022
Q3
$4.22M Buy
31,456
+501
+2% +$71.9K 0.53% 48
2022
Q2
$4.74M Buy
30,955
+218
+0.7% +$33.3K 0.57% 44
2022
Q1
$4.98M Sell
30,737
-4,657
-13% -$676K 0.51% 52
2021
Q4
$4.79M Sell
35,394
-271
-0.8% -$32K 0.48% 50
2021
Q3
$3.85M Buy
35,665
+1,584
+5% +$181K 0.42% 58
2021
Q2
$3.84M Buy
34,081
+3,644
+12% +$410K 0.43% 64
2021
Q1
$3.29M Sell
30,437
-5,808
-16% -$621K 0.41% 68
2020
Q4
$3.88M Sell
36,245
-6,257
-15% -$601K 0.53% 45
2020
Q3
$3.72M Sell
42,502
-10,800
-20% -$1.02M 0.58% 46
2020
Q2
$5.23M Buy
53,302
+7,831
+17% +$689K 0.89% 26
2020
Q1
$3.46M Buy
45,471
+16,038
+54% +$1.37M 0.73% 33
2019
Q4
$2.61M Buy
29,433
+15,548
+112% +$1.29M 0.5% 57
2019
Q3
$1.05M Buy
13,885
+3,748
+37% +$257K 0.23% 123
2019
Q2
$738K Sell
10,137
-1,054
-9% -$82.8K 0.17% 147
2019
Q1
$902K Buy
11,191
+338
+3% +$27.7K 0.21% 122
2018
Q4
$1M Buy
10,853
+470
+5% +$41.3K 0.28% 97
2018
Q3
$982K Buy
10,383
+1,577
+18% +$150K 0.24% 115
2018
Q2
$816K Sell
8,806
-45
-0.5% -$4.39K 0.21% 127
2018
Q1
$838K Sell
8,851
-5,636
-39% -$619K 0.24% 117
2017
Q4
$1.4M Sell
14,487
-224
-2% -$21.1K 0.36% 87
2017
Q3
$1.31M Buy
14,711
+6,400
+77% +$487K 0.37% 83
2017
Q2
$603K Sell
8,311
-22,265
-73% -$1.5M 0.18% 145
2017
Q1
$1.99M Sell
30,576
-4,000
-12% -$251K 0.62% 53
2016
Q4
$2.17M Sell
34,576
-3,200
-8% -$195K 0.69% 40
2016
Q3
$2.38M Sell
37,776
-400
-1% -$25.9K 0.84% 33
2016
Q2
$2.36M Sell
38,176
-150
-0.4% -$9.14K 0.87% 32
2016
Q1
$2.19M Sell
38,326
-2,337
-6% -$130K 0.82% 34
2015
Q4
$2.41M Buy
40,663
+13,000
+47% +$749K 0.95% 23
2015
Q3
$1.5M Buy
27,663
+21,575
+354% +$1.4M 0.65% 44
2015
Q2
$409K Buy
6,088
+1,471
+32% +$96K 0.15% 116
2015
Q1
$270K Hold
4,617
0.11% 135
2014
Q4
$302K Hold
4,617
0.12% 125
2014
Q3
$267K Hold
4,617
0.12% 112
2014
Q2
$261K Hold
4,617
0.11% 135
2014
Q1
$237K Hold
4,617
0.12% 117
2013
Q4
$244K Sell
4,617
-100
-2% -$4.92K 0.11% 119
2013
Q3
$211K Buy
+4,717
New +$209K 0.11% 117

Other funds holding ABBV

Roundview Capital's ABBV Position: Q2 2026 in Review

Roundview Capital increased its AbbVie (ABBV) stake by 2.1% in Q2 2026, buying an estimated $133K and bringing the position to 30,467 shares worth $7.67M. The position accounts for 0.42% of the portfolio, ranked #61.

Roundview Capital first reported a position in ABBV in Q3 2013 and has held it in 52 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Roundview Capital held 30,467 shares of AbbVie worth $7.67M as of Q2 2026.
  • Roundview Capital bought 618 AbbVie shares in Q2 2026, an estimated $133K.
  • AbbVie made up 0.42% of Roundview Capital's portfolio in Q2 2026, its #61 holding.
  • Roundview Capital first reported a position in AbbVie in Q3 2013 and has held it in 52 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Roundview Capital's 13F filing for Q2 2026, filed 30 Jul 2026.